Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan
PUBT · 06/08 11:30
Share
Listen to the news
- Medicus Pharma filed a substantial modification via the EU CTIS to support a planned Phase 2b Teverelix study in advanced prostate cancer.
- The application is under regulatory review; enrollment is targeted for later this year, subject to authorization.
- The trial is intended to support registrational planning focused on prostate cancer patients with elevated cardiovascular risk on androgen deprivation therapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606080730PRIMZONEFULLFEED9733033) on June 08, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved